A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

NCT02439450 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Viagenpumatucel-L
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Pemetrexed

Sponsor

Heat Biologics